ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Cefaclor: Drug information

Cefaclor: Drug information
(For additional information see "Cefaclor: Patient drug information" and see "Cefaclor: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: Canada
  • CO Cefaclor;
  • DOM-Cefaclor
Pharmacologic Category
  • Antibiotic, Cephalosporin (Second Generation)
Dosing: Adult

Note: An ER tablet dose of 500 mg twice daily is clinically equivalent to an IR capsule dose of 250 mg 3 times daily; an ER tablet dose of 500 mg twice daily is NOT clinically equivalent to 500 mg 3 times daily of other cefaclor formulations.

Usual dosage range: Oral:

Immediate release: 250 to 500 mg every 8 hours.

Extended release: 500 mg every 12 hours.

Chronic bronchitis, acute bacterial exacerbation

Chronic bronchitis, acute bacterial exacerbation: Oral: Extended release: 500 mg every 12 hours for 7 days.

Pneumonia, community-acquired, outpatient empiric therapy

Pneumonia, community-acquired, outpatient empiric therapy (patients with comorbidities): Oral: Immediate release: 500 mg every 8 hours as part of an appropriate combination regimen (Ref). Duration is for a minimum of 5 days; patients should be clinically stable with normal vital signs before discontinuing therapy (Ref).

Streptococcal pharyngitis, group A

Streptococcal pharyngitis, group A (alternative agent for mild, nonanaphylactic penicillin allergy):

Note: Cephalosporin selection depends on the type of hypersensitivity reaction to penicillin. To avoid the development of resistance, narrower spectrum cephalosporins (eg, cephalexin or cefadroxil) are preferred when possible (Ref).

Oral: Immediate release: 250 mg every 8 hours for 10 days (Ref).

Urinary tract infection

Urinary tract infection (alternative agent):

Note: Use only when first-line agents cannot be used; limited evidence suggests inferior efficacy of oral beta-lactams (Ref).

Cystitis, acute uncomplicated or acute simple cystitis (infection limited to the bladder without signs/symptoms of upper tract, prostate, or systemic infection), treatment: Oral: Immediate release: 250 mg every 8 hours for 5 to 7 days (Ref).

Cystitis, prophylaxis for recurrent infection (off-label use):

Note: May be considered in nonpregnant women with bothersome, frequently recurrent cystitis despite nonantimicrobial preventive measures. The optimal duration has not been established; duration ranges from 3 to 12 months, with periodic reassessment (Ref).

Continuous prophylaxis: Oral: Immediate release: 250 mg once daily (Ref).

Urinary tract infection, complicated (including pyelonephritis): Oral: Immediate release: 500 mg 3 times daily for 10 to 14 days (Ref). Note: Oral beta-lactam therapy should generally follow appropriate parenteral therapy (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

Manufacturer’s labeling:

Oral:

Mild to severe impairment: No dosage adjustment necessary; use with caution in patients with anuria (half-life is prolonged).

Hemodialysis: There are no dosage adjustments provided in the manufacturer's labeling; hemodialysis shortens half-life by 25% to 30%.

Alternative recommendations (off-label dosing) (Aronoff 2007):

Oral, immediate-release:

Mild to severe impairment: No dosage adjustment necessary.

End-stage renal disease (ESRD) on intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Supplement with 250 to 500 mg after dialysis.

Peritoneal dialysis: Administer 250 to 500 mg every 8 hours.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Cefaclor: Pediatric drug information")

Note: An extended-release tablet dose of 500 mg twice daily is clinically equivalent to an immediate-release capsule dose of 250 mg 3 times daily; an extended-release tablet dose of 500 mg twice daily is NOT clinically equivalent to 500 mg 3 times daily of other cefaclor formulations.

General dosing: Infants, Children, and Adolescents: Immediate release: Oral: 20 to 40 mg/kg/day in divided doses every 8 to 12 hours. Maximum daily dose: 1,000 mg/day (Ref).

Chronic bronchitis, acute bacterial exacerbation

Chronic bronchitis, acute bacterial exacerbation: Adolescents ≥16 years: Extended release: Oral: 500 mg every 12 hours for 7 days.

Lower respiratory tract infection

Lower respiratory tract infection: Note: Despite FDA approval for lower respiratory tract infection, cefaclor is not included in pediatric guidelines for management of community-acquired pneumonia (Ref).

Infants, Children, and Adolescents: Immediate release: Oral: 20 to 40 mg/kg/day divided every 8 hours; maximum daily dose: 1,000 mg/day. For outpatient treatment of uncomplicated community-acquired pneumonia in patients who respond to therapy, 5 days of therapy is likely adequate (Ref). Longer duration (eg, total course of 7 to 10 days) may be necessary in patients with complicated disease or who do not respond quickly to therapy (Ref).

Otitis media

Otitis media: Note: Cefaclor is not a recommended treatment option in the AAP acute otitis media guidelines (Ref).

Infants, Children, and Adolescents: Immediate release: Oral: 40 mg/kg/day in divided doses every 8 to 12 hours for 10 days; maximum daily dose: 1,000 mg/day (Ref).

Skin and soft tissue infection, uncomplicated

Skin and soft tissue infection, uncomplicated: Note: Cefaclor is not currently recommended in IDSA guidelines for treatment of skin and soft tissue infection; alternative agents are preferred (eg, first-generation cephalosporins).

Infants, Children, and Adolescents: Immediate release: Oral: 20 to 40 mg/kg/day divided every 8 hours; maximum daily dose: 1,000 mg/day. Durations as short as 5 days may be appropriate for uncomplicated infections (Ref).

Streptococcus, group A; pharyngitis/tonsillitis

Streptococcus, group A; pharyngitis/tonsillitis (alternative agent for nonanaphylactic penicillin allergy): Note: Narrow-spectrum cephalosporins (eg, cephalexin) are preferred over broader-spectrum cephalosporins such as cefaclor (Ref).

Infants, Children, and Adolescents: Immediate release: Oral: 20 mg/kg/day in divided doses every 8 to 12 hours for 10 days; maximum daily dose: 1,000 mg/day.

Urinary tract infection

Urinary tract infection: Infants, Children, and Adolescents: Immediate release: Oral: 20 to 40 mg/kg/day in divided doses every 8 hours; maximum daily dose: 1,000 mg/day (Ref). Duration of therapy should be individualized based on patient age, severity/extent of infection, and clinical response; uncomplicated cystitis may be treated for 3 to 5 days and pyelonephritis for 6 to 10 days; patients <2 years of age may require a longer course (ie, 7 to 14 days) (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Altered kidney function:

Immediate release:

Infants, Children, and Adolescents:

GFR ≥10 mL/minute/1.73 m2: Oral: No dosage adjustment necessary (Ref).

GFR <10 mL/minute/1.73 m2: Oral: Administer 50% of the recommended dose (Ref).

Extended release: Adolescents ≥16 years: Oral: There are no dosage adjustments provided in the manufacturer's labeling.

Hemodialysis, intermittent:

Note: Hemodialysis shortens half-life by 25% to 30% (Ref).

Immediate release: Infants, Children, and Adolescents: Oral: Administer 50% of the recommended dose; administer after hemodialysis on dialysis days. If not administered after dialysis, administer a supplemental dose following dialysis (Ref).

Extended release: Adolescents ≥16 years: Oral: There are no dosage adjustments provided in the manufacturer's labeling.

Peritoneal dialysis:

Immediate release: Infants, Children, and Adolescents: Oral: Administer 50% of the recommended dose (Ref).

Extended release: Adolescents ≥16 years: Oral: There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

1% to 10%:

Dermatologic: Pruritus (1%)

Gastrointestinal: Abdominal pain (2%), diarrhea (3% to 4%), nausea (3%)

Genitourinary: Genital pruritus (≤2%), vaginitis (≤2%), vulvovaginal candidiasis (≤2%)

Hematologic & oncologic: Eosinophilia (2%)

Hepatic: Increased serum transaminases (3%; including increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased aspartate aminotransferase)

Hypersensitivity: Hypersensitivity reactions (2%)

Nervous system: Headache (5%)

Neuromuscular & skeletal: Back pain (1%)

<1%:

Cardiovascular: Edema (including peripheral edema) (Romano 2008), heart failure, palpitations

Dermatologic: Diaphoresis, maculopapular rash (Romano 2008), skin rash, urticaria (Romano 2008)

Endocrine & metabolic: Decreased serum albumin, decreased serum calcium, decreased serum sodium, increased gamma-glutamyl transferase, increased serum phosphate, increased serum potassium, increased serum sodium, menstrual disease

Gastrointestinal: Anorexia, constipation, dyspepsia, flatulence, gastritis, vomiting

Genitourinary: Abnormal urine test finding, dysmenorrhea, dysuria, leukorrhea, nocturia

Hematologic & oncologic: Decreased hemoglobin, decreased red blood cells, increased MCV, lymphocytopenia, positive direct Coombs’ test, thrombocytopenia

Hepatic: Increased serum bilirubin

Hypersensitivity: Serum sickness

Nervous system: Anxiety, dizziness, drowsiness, insomnia, malaise, nervousness, pain, tremor

Neuromuscular & skeletal: Arthralgia, increased creatine phosphokinase in blood specimen, myalgia, neck pain

Renal: Increased blood urea nitrogen, increased serum creatinine, interstitial nephritis

Respiratory: Asthma

Postmarketing:

Cardiovascular: Hypotension, syncope, vasodilation

Dermatologic: Acute generalized exanthematous pustulosis (Kwah 2005), erythema of skin (Romano 2008), Stevens-Johnson syndrome, toxic epidermal necrolysis

Gastrointestinal: Clostridioides difficile colitis

Hematologic & oncologic: Agranulocytosis, aplastic anemia, hemolytic anemia, leukopenia, neutropenia

Hepatic: Cholestatic jaundice, hepatitis

Hypersensitivity: Anaphylactic shock (Romano 2008), anaphylaxis (Grouhi 1999), angioedema (Romano 2008), facial edema, nonimmune anaphylaxis

Nervous system: Agitation, confusion, hallucination, hypertonia, hyperactive behavior, paresthesia, vertigo

Contraindications

Hypersensitivity to cefaclor, other cephalosporins, or any component of the formulation.

Warnings/Precautions

Concerns related to adverse effects:

• Hypersensitivity: Anaphylactic reactions have occurred. If a serious hypersensitivity reaction occurs, discontinue and institute emergency supportive measures, including airway management and treatment (eg, epinephrine, antihistamines, and/or corticosteroids).

• Penicillin allergy: Use with caution in patients with a history of penicillin allergy.

• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.

Disease-related concerns:

• Gastrointestinal disease: Use with caution in patients with a history of gastrointestinal disease, particularly colitis.

• H. influenzae infections: Beta-lactamase-negative, ampicillin-resistant (BLNAR) strains of H. influenzae should be considered resistant to cefaclor.

• Renal impairment: Use with caution in patients with renal impairment.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer’s labeling.

• Extended-release tablet: An extended-release tablet dose of 500 mg twice daily is clinically equivalent to an immediate-release capsule dose of 250 mg 3 times daily; an extended-release tablet dose of 500 mg twice daily is NOT clinically equivalent to 500 mg 3 times daily of other cefaclor formulations.

Warnings: Additional Pediatric Considerations

Cefaclor may cause serum sickness-like reaction, which has been reported more frequently in pediatric patients, particularly in patients <5 years of age. The exact incidence of serum sickness-like reaction after a course of cefaclor is uncertain but is likely between 0.024% and 0.5%. Reactions typically involve urticarial rash (often pruritic and migratory) and joint swelling, arthritis, or arthralgia (commonly in hands, feet, or knees), with or without fever, and most often occur with a second or third exposure; severity ranges from mild to severe. Signs and symptoms typically appear around 1 week after cefaclor initiation, but may appear as early as 2 days and as late as 21 days later, and resolve within a few days of discontinuation; joint symptoms may take longer to resolve. Repeat use is not recommended in patients who have previously experienced a serum sickness-like reaction while receiving cefaclor (Hebert 1991; Heckbert 1990; Isaacs 2001; Levine 1985; Martin 1995; Parshuram 1999; Vial 1992; manufacturer's labeling).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Capsule, Oral:

Generic: 250 mg, 500 mg

Suspension Reconstituted, Oral:

Generic: 125 mg/5 mL (150 mL [DSC]); 250 mg/5 mL (150 mL); 375 mg/5 mL (100 mL [DSC])

Tablet Extended Release 12 Hour, Oral:

Generic: 500 mg

Generic Equivalent Available: US

Yes

Pricing: US

Capsules (Cefaclor Oral)

250 mg (per each): $2.59

500 mg (per each): $5.06

Suspension (reconstituted) (Cefaclor Oral)

250 mg/5 mL (per mL): $4.62

Tablet, 12-hour (Cefaclor ER Oral)

500 mg (per each): $23.32

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral:

Generic: 250 mg, 500 mg

Administration: Adult

Oral:

Capsules and oral suspension: Administer without regard to meals; shake oral suspension well before using

ER tablets: Do not chew, crush, or split; administer with or within 1 hour of food.

Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Switch to IR formulation. Capsule may be opened and contents sprinkled onto soft food of choice. Patient should be instructed to swallow the mixture without biting down or chewing.

Administration: Pediatric

Oral:

Capsules and oral suspension: Administer without regard to meals; shake oral suspension well before using.

Extended-release tablets: Do not chew, crush, or split; administer with or within 1 hour of food.

Use: Labeled Indications

Acute bacterial exacerbations of chronic bronchitis (extended-release tablets only): Treatment of acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding beta-lactamase-negative, ampicillin-resistant strains only), Moraxella catarrhalis, or Streptococcus pneumoniae.

Lower respiratory tract infections (capsules and oral suspension only): Treatment of lower respiratory tract infections, including pneumonia, caused by S. pneumoniae, H. influenzae, and Streptococcus pyogenes.

Otitis media (capsules and oral suspension only): Treatment of otitis media caused by S. pneumoniae, H. influenzae, staphylococci, and S. pyogenes.

Skin and skin structure infections, uncomplicated: Treatment of uncomplicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible) or S. pyogenes (capsules and oral suspension only).

Streptococcal pharyngitis, group A: Treatment of pharyngitis and tonsillitis due to S. pyogenes.

Urinary tract infection (capsules and oral suspension only): Treatment of urinary tract infections, including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp, and coagulase-negative staphylococci.

Medication Safety Issues
Sound-alike/look-alike issues:

Cefaclor may be confused with cephalexin

Metabolism/Transport Effects

Substrate of OAT1/3

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Aminoglycosides: Cephalosporins may enhance the nephrotoxic effect of Aminoglycosides. Cephalosporins may decrease the serum concentration of Aminoglycosides. Risk C: Monitor therapy

Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii. Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy. Risk D: Consider therapy modification

BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination

BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Risk C: Monitor therapy

Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Risk X: Avoid combination

Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics. Risk X: Avoid combination

Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). Risk X: Avoid combination

Furosemide: May enhance the nephrotoxic effect of Cephalosporins. Risk C: Monitor therapy

Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). Risk C: Monitor therapy

Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Risk C: Monitor therapy

Probenecid: May increase the serum concentration of Cephalosporins. Risk C: Monitor therapy

Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Risk D: Consider therapy modification

Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Avoid use of live attenuated typhoid vaccine (Ty21a) in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose. Risk D: Consider therapy modification

Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. Risk C: Monitor therapy

Food Interactions

The bioavailability of cefaclor extended-release tablets is decreased 23% and the maximum concentration is decreased 67% when taken on an empty stomach. Management: Administer with food.

Pregnancy Considerations

An increased risk of teratogenic effects has not been observed following maternal use of cefaclor.

Breastfeeding Considerations

Small amounts of cefaclor are excreted in breast milk. The manufacturer recommends that caution be exercised when administering cefaclor to nursing women. Nondose-related effects could include modification of bowel flora.

Dietary Considerations

Extended release tablets should be taken with or within 1 hour of food.

Monitoring Parameters

Monitor renal function. Observe for signs of anaphylaxis during first dose.

Mechanism of Action

Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs), which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.

Pharmacokinetics (Adult Data Unless Noted)

Absorption: Oral: Well absorbed; acid stable.

Distribution: Distributes into tissues and fluids including bone, pleural and synovial fluid.

Protein binding: 25% (Aronoff 2007).

Half-life elimination:

Infants ≥4 months and Children ≤5 years: Mean range: 36 to 60 minutes (McCracken 1978).

Adults: 0.6 to 0.9 hours; prolonged with renal impairment (2.3 to 2.8 hours in anuria).

Time to peak: Capsules, oral suspension: 30 to 60 minutes; Extended-release tablets: 2.5 hours.

Excretion: Urine (60% to 85% as unchanged drug).

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Anti-infective considerations:

Parameters associated with efficacy:

Time dependent; associated with time free drug concentration (fT) > minimum inhibitory concentration (MIC): Goal: ≥40% to 50% (fT) > MIC (bacteriostatic), 60% to 70% (fT) > MIC (bactericidal) (Cazzola 2000; Craig 1996; Craig 1998; Turnidge 1998).

Expected drug exposure in patients with normal renal function:

Infants ≥4 months and Children ≤5 years: Cmax (peak): Steady state, immediate release: 10 mg/kg/dose every 6 hours: 6.7 mg/L (fed), 10.8 mg/L (fasting) (McCracken 1978).

Adults, Cmax (peak):

Single dose, delayed release: 750 mg: ~8.6 mg/L (Cazzola 2000; Tomić 2016).

Steady state, immediate release: 500 mg every 8 hours: 15.2 ± 4.75 mg/mL (Barbhaiya 1990).

Postantibiotic effect: Generally <1 hour; varies based on organism (Craig 1991; Craig 1998; Dubois 2000).

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Ceclocare | Ceclor | Cloracef | Cloracef mr | Recocef | Tabiclor | Vercef;
  • (AR) Argentina: Cec | Cefaclor fabra | Cefaclor richet | Cefloboxal | Distaclor | Kwicap;
  • (AT) Austria: Cec | Ceclor | Ceclor duo | Cefastad;
  • (AU) Australia: Aclor | Apo-cefaclor | Apo-cefaclor cd | Ceclor | Cefaclor cd | Cefaclor sandoz | Cefaclor-bc | Cefaclor-GA | Cefkor | Cefkor cd | Cm cefaclor | Dbl cefaclor | Karlor | Karlor cd | Keflor | Ozcef | Tw cefaclor;
  • (BD) Bangladesh: Abaclor | Alclor | Biocef | Ceclor | Cefclor | Ceflon | Cfl | Clocef | Clorocef | Loracef | Navacef | Oticef | Oticlor | Sefalor;
  • (BE) Belgium: Ceclor | Doccefaclo;
  • (BG) Bulgaria: Cec | Ceclor | Medoclor | Razicef;
  • (BR) Brazil: Ceclor | Ceclor af | Ceclor bd | Cefaclor monoidratado | Cefacloren | Clorcin-ped | Faclor | Novacef | Plecor | Reflax;
  • (CH) Switzerland: Ceclor;
  • (CI) Côte d'Ivoire: Alfatil | Bacticef | Oralcef;
  • (CL) Chile: Keflor;
  • (CN) China: Bi li | Ceclor | Cefaclor stada | Ji da you ka | Jinshi ke zhi | Ke fu le | Ke luo | Keflor | Lai fu luo | Man ning | Ou jia | Sheng han | Shi hua luo | Shuai xian | Su ke le | Xi fu lai | Xi you luo | Xin da luo | Xin ke nuo | Xincatlor | You ke luo;
  • (CO) Colombia: Ceclor | Distaclor;
  • (CZ) Czech Republic: Alfacet | Cec | Ceclor | Cefaclor al | Serviclor | Vercef;
  • (DE) Germany: Cec | Ceclorbeta | Cef diolan | Cefa wolff | Cefaclor 1a pharma | Cefaclor al | Cefaclor Aristo | Cefaclor beta | Cefaclor CT | Cefaclor ratiopharm | Cefaclor sandoz | Cefaclor stada | Cefaclor wolff | Cephalodoc | Hefaclor | Infectocef | Sigacefal;
  • (DO) Dominican Republic: Cec | Ceclor | Cefaclor feltrex | Cefaltrex | Cefamid | Cefcor | Cefcor MR | Cefin | Clorcefor | Clorotir | Falcef | Infaclor | Loclor | Lufraclor | Suclor;
  • (EC) Ecuador: Ceclor | Cefraspor;
  • (EE) Estonia: Ceclor;
  • (EG) Egypt: Bacticlor | Ceclor | Cefaclor | Cloracef | Clorocef | Misaclor | Serviclor;
  • (ES) Spain: Ceclor | Cefaclor bexal | Cefaclor normon;
  • (ET) Ethiopia: Tabiclor;
  • (FI) Finland: Cefaklor ranbaxy | Kefolor;
  • (FR) France: Alfatil | Alphexine | Cefaclor G Gam | Cefaclor merck | Cefaclor rpg;
  • (GB) United Kingdom: Bacticlor mr | Cefaclor cox | Cefaclor kent | Cefaclor sandoz | Distaclor | Keftid;
  • (GR) Greece: Afecton | Camirox | Ceclor | Cefacloril | Makovan;
  • (HK) Hong Kong: Castal | Ceclor | Ceclorin | Cefalor | Clortrin | Medoclor | Neo clora | Phaclor | Quali-ceclor | Qualiphor | Soficlor | Syntoclor | Vercef;
  • (HU) Hungary: Ceclor | Cecloretta | Cefaclor al | Cefaclor ratiopharm | Serviclor | Vercef;
  • (ID) Indonesia: Capabiotic | Ceclor | Ceflex | Cloracef | Especlor | Forifek | Medikoncef | Soclor;
  • (IE) Ireland: Cefager | Distaclor | Keftid | Pinaclor;
  • (IL) Israel: Ceclor | Cefalor;
  • (IN) India: Articlor | Clorocef | Distaclor | Duclor | Eclor | Eclor premix | Halclor | Halocef | Keflor | Radiclor | Uniclor | Vercef | Zenclor;
  • (IT) Italy: Altaclor | Bacticef | Bactigram | Cefaclor doc | Cefaclor eg | Cefaclor K24 | Cefulton | Citiclor | Clorad | Clorazer | Dorf | Erreclor | Eurocefix | Fuclode | Geniclor | Kliacef | Lafarclor | Macovan | Necloral | Oralcef | Panacef | Performer | Selanir | Selviclor | Takecef | Tibifor | Valeclor;
  • (JO) Jordan: Biocef | Ceclor | Cefabac | Cloracef | Forbatec | Midocef | Pharmaclor;
  • (JP) Japan: Alenfral | Alenfral choseido | Ccl | Ceclodan | Cefaclor maruko | Ericanal | Hishiyachlor | Kefpolin | Kefral | Kulilel amel | Kulilel mita | Kulilel tatumi | Ruberal isei | Ruberal tobishi | Saltskural | Saltskural kayaku | Saltskural shiono | Tofarol | Tokiclor;
  • (KE) Kenya: Cefclor | Clofort | Halocef | Labclor | Medacef | Vercef;
  • (KR) Korea, Republic of: Ahngook cefaclor | Aju cefaclor | Alvogen cefaclor hydrate | Anticle | Anticlor | Antilor | Aprogen cefaclor | Arlico cefaclor | Auclor | Biclor | Biclor sr | Binex cefaclor | Bm cefaclor | Cecid | Cecl | Cecla | Ceclem | Ceclen | Ceclex | Ceclin | Ceclor | Ceclor mr | Cecra | Cecradin sr | Cecrocin | Cecrun | Cectin | Cefa | Cefa s | Cefacid | Cefacide | Cefacl | Cefacla | Cefacle | Cefaclean | Cefacli | Cefaclin | Cefaclin er | Cefaclor | Cefaclor Asia | Cefaclor cap. boryung | Cefaclor capsule 250 mg rp | Cefaclor Chunggei | Cefaclor dry syrup sk | Cefaclor guju | Cefaclor ss | Cefaclridid | Cefacool | Cefacro | Cefaculor | Cefacure | Cefalasin | Cefalex | Cefalex sr | Cefalon | Cefalor | Cefapos | Cefarasin | Cefaro | Cefarox | Cefazine | Ceficle | Cefler | Cefnil | Ceforin | Cefotamin | Cefotamin sr | Cefre | Celfaclor | Celor | Cenaf | Cencla | Cepclor | Ceracl | Cerecle | Cereo | Cerocle | Cesid | Cevacl | Citclor | Cleancef | Clex | Clif | Clocef | Clorwin | Cmg cefaclor | Cofacle | Cyclor | Dae hwa cefaclor | Daewoo cefaclor | Dongkoo cefaclor hydrate | Dongkoo cefaclor sr | Dongwha cefaclor | Eden cefaclor | Elclor | Esclor | Facle | Faclerin | Faclor | Facro | Fronclor | Glo cefaclor sr | Hanaclor | Hucefa | Huclor | Huniz cefaclor | Hyundai cefaclor | Icefa | Il yang cefaclor | Ildong cefaclor | Ilhwa cefaclor | Ilyangbio cefaclor | Itclor | Jeclor | Joonclor | Jr cefaclor | Jw cefaclor | Kdc cefaclor | Kemocin | Kepla | Kms cefaclor | Korus cefaclor | Kwangdong cefaclor | Kyongbo cefaclor | Litecefa | Medica cefaclor | Medica cefaclor sr | Micla | Miclor | Myungin cefaclor | Myungmoon cefaclor | Nelson cefaclor | Neocef | Newcefa | Newclor | Newfaclor | Newgen cefaclor retard | Newgenclor | Newporin | Newporine | Nuclor | Nuclur | Olcefa | Oraclor | Panacef | Pharma cefaclor sr | Pharmaking cefaclor | Pharmgen cefaclor | Pharvis cefaclor | Sake | Samnam cefaclor | Samsung cefaclor | Sebacle | Secl | Seclor | Seporin | Sera | Sinil cefaclor | Spc cefaclor | Syntex cefaclor | Taiguk cefaclor | Uniclor | Withus cefaclor | Wonclor | Wooridul cefaclor | Youngil cefaclor | Youngpoong cefaclor | Yuhan cefaclor | Yuhan cefaclor sr | Yungjin cefaclor | Yuyu cefaclor | Zecra;
  • (KW) Kuwait: Ceclocare | Ceclor | Ceclor mr | Cefabac | Cloracef | Cloracef mr | Medacef | Recocef | Tabiclor | Vercef;
  • (LB) Lebanon: Ceclor | Cloracef | Cloracef mr | Zeflox;
  • (LT) Lithuania: Cec | Ceclor | Vercef;
  • (LU) Luxembourg: Cec | Ceclor | Doccefaclo;
  • (LV) Latvia: Ceclor | Vercef;
  • (MA) Morocco: Alfacefal | Alfatil | Cloracef | Clorotir;
  • (MX) Mexico: Arcefal | Bixelor C | Bixelor c | Cec | Ceclor | Cefaclor Ranbaxy | Cefalan | Cefalan mr | Ceflacid | Fasiclor | Fluban | Inclor | Ranclor | Serviclor | Tecnoclor | Teraclox;
  • (MY) Malaysia: Axcel Cefaclor | Cefalon | Efaclor | Sefaclor | Sifaclor | Soficlor | Vercef;
  • (NL) Netherlands: Ceclor | Cefaclor sandoz;
  • (NZ) New Zealand: Ceclor | Ceclor cd | Cefaclor sandoz | Clorotir | Keflor | Ranbaxy cefaclor;
  • (PE) Peru: Ceclomek | Ceclor | Cefabac | Cefatrim | Cefcor | Cefraspor | Clorotir | Gramactam | Infaclor | Oraclor | Panacef;
  • (PH) Philippines: Brelox | Ceclobid | Ceclor | Cecrocef | Cefaclor Am-Europharma | Cefar | Ceflor | Cefmed | Cfc | Cloran | Clorcef | Clorgen | Clormed | Clorotir | Ephron | Lorcef | Reclor | Remedlor | Rimaclor | Tgp genclor | Vefarol | Vercef | Verzat | Xelent | Xeztron | Zifclor | Zyrcef;
  • (PK) Pakistan: Afalor | Ag-Clor | Cariclor | Cavalor | Ceclor | Ceclor mr | Cefa Z | Cefalor | Cefanol | Cefatek | Cefawan | Cefclor | Cefgard | Ceflis | Cefmoni | Cefolom | Cefticlor | Cekrol | Cephlo | Cetaclor | Cloratec | Clorex | Clorizat | Corvin | Danvar | Deduclol | Deucef | Distaclor | Enspor | Exlor | Geflor | Hiclor | Inclor | Ipraclor | Kilbac | Klorex | Lexiclor | Meclor | Medclor | Misflor | N clor | Nettle | Neutroclor | Niflor | Pechlor | Plorsaf | Plozat | Proclor | Reclor | Ridbac | Ridclor | Ridclor ds | Sac lor | Sayflar | Seclor | Slate | Slate mr | Sn ceflor | Sn faclor | Soclar | Supren | Teklor | Trinkle | Varco | Vesclor | W Clor | X clor | Zuper;
  • (PL) Poland: Alfacet | Apo-cefaclor | Ceclor | Cek | Kloracef | Panclor | Serviclor | Vercef;
  • (PR) Puerto Rico: Ceclor | Ceclor cd | Cefaclor | Cefaclor extended release;
  • (PT) Portugal: Ceclor;
  • (QA) Qatar: Ceclor | Ceclor MR | Cloracef | Cloracef Forte | Medacef | Tabiclor | Tabiclor MR;
  • (RO) Romania: Ceclodyne mr | Ceclor | Ceclor mr | Ceclozone MR | Cefaclor arena | Cefaclor terapia | Cefaklor | Cloracef;
  • (RU) Russian Federation: Alfacet | Ceclor | Cefaclor stada | Vercef;
  • (SA) Saudi Arabia: Biocef | Ceclor | Cloracef | Forticef | Medacef | Recocef | Tabiclor;
  • (SE) Sweden: Kefolor;
  • (SG) Singapore: Cleancef | Soficlor | Vercef;
  • (SI) Slovenia: Ceclor | Cefa cl | Taracef;
  • (SK) Slovakia: Ceclor | Serviclor | Vercef;
  • (TH) Thailand: Cecef R | Ceclor | Cefaclor stada | Cefclorstar | Celco | Clorotir | Distaclor | Hofclor | Kressclor | Sifaclor | Ufaclor | Vercef;
  • (TN) Tunisia: Alfatil;
  • (TR) Turkey: Ceclor | Cekloteva | Kefsid | Losefar | Sanocef;
  • (TW) Taiwan: Alfacol | Cefac | Cefachlor | Cefalo | Cekor | Celor | Cero | Keflor | Keflor af | Keflu | Kerfenmycin | Kerloli | Rolfec | Swiflor | U-clor | Uclor;
  • (UA) Ukraine: Biclor | Ceclor | Vercef;
  • (UG) Uganda: Hiclor | Recocef;
  • (VE) Venezuela, Bolivarian Republic of: Ceclor;
  • (VN) Viet Nam: Dazofort | Imeclor | Kefcin;
  • (ZA) South Africa: Adco-cefaclor | Cec | Ceclor | Cloracef | Lilly-cefaclor | Rolab-cefaclor | Vercef;
  • (ZM) Zambia: Lilly-cefaclor;
  • (ZW) Zimbabwe: Vercef
  1. Afolabi TM, Goodlet KJ, Fairman KA. Association of antibiotic treatment duration with recurrence of uncomplicated urinary tract infection in pediatric patients. Ann Pharmacother. 2020;54(8):757-766. doi:10.1177/1060028019900650 [PubMed 31958969]
  2. Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
  3. American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. Red Book: 2021 Report of the Committee on Infectious Diseases. 32nd ed. American Academy of Pediatrics; 2021.
  4. American Thoracic Society, “Guidelines for the Initial Management of Adults With Community-Acquired Pneumonia: Diagnosis, Assessment of Severity, and Initial Antimicrobial Therapy,” Am Rev Respir Dis, 1993, 148(5):1418-26. [PubMed 8239186]
  5. Anger J, Lee U, Ackerman AL, et al. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline. J Urol. 2019;202(2):282-289. doi:10.1097/JU.0000000000000296 [PubMed 31042112]
  6. Aronoff GR, Bennett WM, Berns JS, et al, Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 61, 153.
  7. Balighian E, Burke M. Urinary tract infections in children. Pediatr Rev. 2018;39(1):3-12. doi:10.1542/pir.2017-0007 [PubMed 29292282]
  8. Barbhaiya RH, Shukla UA, Gleason CR, et al. Phase I study of multiple-dose cefprozil and comparison with cefaclor. Antimicrob Agents Chemother. 1990;34(6):1198-1203. doi:10.1128/AAC.34.6.1198 [PubMed 2393281]
  9. Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: Clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America (PIDS/IDSA). Clin Infect Dis. 2011;53(7):e25-76. doi:10.1093/cid/cir531 [PubMed 21880587]
  10. Bradley JS, Nelson JD, Kimberlin DK, et al, eds. Nelson's Pocket Book of Pediatric Antimicrobial Therapy. 28th ed. American Academy of Pediatrics; 2022.
  11. Brumfitt W, Hamilton-Miller JM. A comparative trial of low dose cefaclor and macrocrystalline nitrofurantoin in the prevention of recurrent urinary tract infection. Infection. 1995;23(2):98-102. doi:10.1007/BF01833874 [PubMed 7622272]
  12. Campagna JD, Bond MC, Schabelman E, Hayes BD. The use of cephalosporins in penicillin-allergic patients: a literature review. J Emerg Med. 2012; 42(5):612-620. [PubMed 21742459]
  13. Cazzola M, Di Perna F, Boveri B, Di Marco F, Diamare F, Centanni S. Interrelationship between the pharmacokinetics and pharmacodynamics of cefaclor advanced formulation in patients with acute exacerbation of chronic bronchitis. J Chemother. 2000;12(3):216-222. doi:10.1179/joc.2000.12.3.216 [PubMed 10877516]
  14. Cefaclor capsules [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; November 2020.
  15. Cefaclor extended-release tablets [prescribing information]. North Wales, PA: Teva Pharmaceuticals; July 2019.
  16. Cefaclor for oral suspension, USP [prescribing information]. Claymont, DE: Azorian Pharma LLC; April 2022.
  17. Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084]
  18. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J. 1996;15(3):255-259. doi:10.1097/00006454-199603000-00015 [PubMed 8852915]
  19. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1-10;quiz 11-2. doi:10.1086/516284 [PubMed 9455502]
  20. Craig WA. The postantibiotic effect. CMNEEJ. 1991;13(16)121-128.
  21. Donowitz GR and Mandell GL, “Beta-Lactam Antibiotics,” N Engl J Med, 1988, 318(7):419-26 and 318(8):490-500. [PubMed 3277054]
  22. Dubois J, St-Pierre C. In vitro study of the post-antibiotic effect and the bactericidal activity of Cefditoren and ten other oral antimicrobial agents against upper and lower respiratory tract pathogens. Diagn Microbiol Infect Dis. 2000;37(3):187-193. doi:10.1016/s0732-8893(00)00141-3 [PubMed 10904192]
  23. Fox MT, Amoah J, Hsu AJ, Herzke CA, Gerber JS, Tamma PD. Comparative effectiveness of antibiotic treatment duration in children with pyelonephritis. JAMA Netw Open. 2020;3(5):e203951. doi:10.1001/jamanetworkopen.2020.3951 [PubMed 32364593]
  24. Grouhi M, Hummel D, Roifman CM. Anaphylactic reaction to oral cefaclor in a child. Pediatrics. 1999;103(4):e50. doi:10.1542/peds.103.4.e50 [PubMed 10103342]
  25. Gupta K. Recurrent simple cystitis in women. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 11, 2021.
  26. Gupta K, Hooton TM, Naber KG, et al; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103-e120. doi: 10.1093/cid/ciq257. [PubMed 21292654]
  27. Hebert AA, Sigman ES, Levy ML. Serum sickness-like reactions from cefaclor in children. J Am Acad Dermatol. 1991;25(5, pt 1):805-808. doi:10.1016/s0190-9622(08)80973-5 [PubMed 1802903]
  28. Heckbert SR, Stryker WS, Coltin KL, Manson JE, Platt R. Serum sickness in children after antibiotic exposure: estimates of occurrence and morbidity in a health maintenance organization population. Am J Epidemiol. 1990;132(2):336-342. doi:10.1093/oxfordjournals.aje.a115663 [PubMed 2115293]
  29. Hooton TM, Gupta K. Acute complicated urinary tract infection (including pyelonephritis) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 20, 2021b.
  30. Hyslop DL. Cefaclor Safety Profile: A Ten Year Review. Clin Ther. 1988;11(suppl A):83-94. [PubMed 3242837]
  31. Hyslop DL, Bischoff W. Loracarbef (LY163892) versus cefaclor and norfloxacin in the treatment of uncomplicated pyelonephritis. Am J Med. 1992;92(6A):86S-94S. doi:10.1016/0002-9343(92)90614-h [PubMed 1621752]
  32. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
  33. Iravani A. Loracarbef versus cefaclor in the treatment of cystitis and asymptomatic bacteriuria. Clin Ther. 1992;14(1):54-63. [PubMed 1576626]
  34. Isaacs D. Serum sickness-like reaction to cefaclor. J Paediatr Child Health. 2001;37(3):298-299. doi:10.1046/j.1440-1754.2001.00632.x [PubMed 11468048]
  35. Kuitunen I, Jääskeläinen J, Korppi M, Renko M. Antibiotic treatment duration for community acquired pneumonia in outpatient children in high-income countries - a systematic review and meta-analysis. Clin Infect Dis. 2022;ciac374. doi:10.1093/cid/ciac374 [PubMed 35579504]
  36. Kwah YC, Leow YH. Not all pustules are infective in nature: acute generalised exanthematous pustulosis causing pustular eruptions in an elderly woman. Singapore Med J. 2005;46(7):349-351. [PubMed 15968449]
  37. Lashkar MO, Nahata MC. Antimicrobial pharmacotherapy management of urinary tract infections in pediatric patients. J Pharm Technol. 2018;34(2):62-81. doi:10.1177/8755122518755402 [PubMed 34860955]
  38. Leigh AP, Nemeth MA, Keyserling CH, Hotary LH, Tack KJ. Cefdinir versus cefaclor in the treatment of uncomplicated urinary tract infection. Clin Ther. 2000;22(7):818-825. doi:10.1016/s0149-2918(00)80054-5 [PubMed 10945508]
  39. Levine LR, “Quantitative Comparison of Adverse Reactions to Cefaclor vs Amoxicillin in a Surveillance Study,” Pediatr Infect Dis, 1985, 4(4):358-61. [PubMed 3161007]
  40. Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. Pediatrics. 2013;131(3):e964-999. [PubMed 23439909]
  41. Marshall WF and Blair JE, “The Cephalosporins,” Mayo Clin Proc, 1999, 74(2):187-95. [PubMed 10069359]
  42. Martin J, Abbott G. Serum sickness like illness and antimicrobials in children. N Z Med J. 1995;108(997):123-124. [PubMed 7739819]
  43. McCracken GH Jr, Ginsburg CM, Clahsen JC, Thomas ML. Pharmacokinetics of cefaclor in infants and children. J Antimicrob Chemother. 1978;4(6):515-521. doi:10.1093/jac/4.6.515 [PubMed 711649]
  44. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST [PubMed 31573350]
  45. Parshuram CS, Phillips RJ, Nash MC. Serum sickness in a paediatric emergency department: the role of cefaclor. J Paediatr Child Health. 1999;35(2):223-224. [PubMed 10365368]
  46. Pernica JM, Harman S, Kam AJ, et al. Short-course antimicrobial therapy for pediatric community-acquired pneumonia: the SAFER Randomized Clinical Trial. JAMA Pediatr. 2021;175(5):475-482. doi:10.1001/jamapediatrics.2020.6735 [PubMed 33683325]
  47. Pichichero ME. Treatment and prevention of streptococcal pharyngitis in adults and children. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 12, 2022.
  48. Refer to manufacturer's labeling.
  49. Rodriguez WJ, Khan W, Sait T, et al. Cefixime vs. cefaclor in the treatment of acute otitis media in children: a randomized, comparative study. Pediatr Infect Dis J. 1993;12(1):70-74. doi:10.1097/00006454-199301000-00015 [PubMed 8417429]
  50. Romano A, Gaeta F, Valluzzi RL, Alonzi C, Viola M, Bousquet PJ. Diagnosing hypersensitivity reactions to cephalosporins in children. Pediatrics. 2008;122(3):521-527. doi:10.1542/peds.2007-3178 [PubMed 18762521]
  51. Same RG, Amoah J, Hsu AJ, et al. The association of antibiotic duration with successful treatment of community-acquired pneumonia in children. J Pediatric Infect Dis Soc. 2021;10(3):267-273. doi:10.1093/jpids/piaa055 [PubMed 32525203]
  52. Saxon A, Beall GN, Rohr AS, et al, “Immediate Hypersensitivity Reactions to Beta-Lactam Antibiotics,” Ann Intern Med, 1987, 107(2):204-15. [PubMed 3300459]
  53. Shulman ST, Bisno AL, Clegg HW, et al; Infectious Diseases Society of America. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis. 2012;55(10):e86-102. doi:10.1093/cid/cis629 [PubMed 22965026]
  54. Smith GH, “Oral Cephalosporins in Perspective,” DICP, 1990, 24(1):45-51. [PubMed 2405586]
  55. Stein R, Dogan HS, Hoebeke P, et al. Urinary tract infections in children: EAU/ESPU guidelines. Eur Urol. 2015;67(3):546-558. doi:10.1016/j.eururo.2014.11.007 [PubMed 25477258]
  56. Stevens DL, Bisno AL, Chambers HF, et al; Infectious Diseases Society of America (IDSA). Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52. doi:10.1093/cid/ciu444 [PubMed 24973422]
  57. Terico AT, Gallagher JC. Beta-lactams hypersensitivity and cross-reactivity. J Pharm Pract. 2014;27(6):530-544. [PubMed 25124380]
  58. 't Hoen LA, Bogaert G, Radmayr C, et al. Update of the EAU/ESPU guidelines on urinary tract infections in children. J Ped Urol. 2021;17(2):200-207. doi:10.1016/j.jpurol.2021.01.037 [PubMed 33589366]
  59. Tomić Z, Tomas A, Vukmirović S, et al. Do we bury antibacterials when launching? Cefaclor example. J Pharm Sci. 2016;105(3):1295-1300. doi:10.1016/j.xphs.2015.12.003 [PubMed 26886327]
  60. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis. 1998;27(1):10-22. doi:10.1086/514622 [PubMed 9675443]
  61. Vial T, Pont J, Pham E, Rabilloud M, Descotes J. Cefaclor-associated serum sickness-like disease: eight cases and review of the literature. Ann Pharmacother. 1992;26(7-8):910-914. doi:10.1177/106002809202600708 [PubMed 1504397]
  62. Williams DJ, Creech CB, Walter EB, et al. Short- vs standard-course outpatient antibiotic therapy for community-acquired pneumonia in children: the SCOUT-CAP randomized clinical trial. JAMA Pediatr. 2022;176(3):253-261. doi:10.1001/jamapediatrics.2021.5547 [PubMed 35040920]
  63. Wright AJ, “The Penicillins,” Mayo Clin Proc, 1999, 74(3):290-307. [PubMed 10090000]
Topic 9211 Version 298.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟